-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, DH9ACyv0qQFuxeGcDtH4RaJMQL+O+EDYqbGQvkQLsRhyKTCppLltsbEPus4zOQ7A u/AysmZfKZjEwyBrXecknw== 0001367982-07-000294.txt : 20070703 0001367982-07-000294.hdr.sgml : 20070703 20070703145104 ACCESSION NUMBER: 0001367982-07-000294 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070702 FILED AS OF DATE: 20070703 DATE AS OF CHANGE: 20070703 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gergen Mark J CENTRAL INDEX KEY: 0001373110 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 07960123 BUSINESS ADDRESS: BUSINESS PHONE: 858-552-2200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2007-07-02 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001373110 Gergen Mark J 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 Sr VP, Corporate Development Common Stock 2007-07-02 4 M 0 500 16.8 A 3437 D Common Stock 2007-07-02 4 S 0 500 41.2 D 2937 D Non-Qualified Stock Option (right to buy) 16.8 2007-07-02 4 M 0 500 0 D 2015-05-09 Common Stock 500 22436 D This sale was affected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. One-fourth (1/4) of this option grant vested on May 9, 2006 with the remainder of the grant vesting monthly over the next three years becoming fully-vested four years from the date of grant. By: /s/Lloyd A. Rowland, Attorney-in-Fact For: Mark J. Gergen 2007-07-03 -----END PRIVACY-ENHANCED MESSAGE-----